Engineered a stable, high-expressing bispecific antibody for oncology, achieving 1.8 g/L yield with excellent stability for IND-enabling studies.
A biotech startup was developing a novel bispecific antibody for oncology, facing significant challenges with expression, stability, and manufacturability of this complex molecule.
Bispecific antibodies are inherently difficult to produce due to their complex structure and potential for mispairing, making stable, high-expressing cell lines challenging to develop.